NucleoBio

NucleoBio is a molecular diagnostics company focused on developing ultra-sensitive platforms for the rapid detection of nucleic acids. The company's core technology, Nucleo-LOD, enables the detection of pathogens and biomarkers at significantly lower limits than traditional PCR methods, facilitating earlier diagnosis and intervention. NucleoBio's product portfolio includes point-of-care and laboratory-based tests for infectious diseases such as COVID-19, influenza, and RSV, as well as applications in oncology for liquid biopsy. By streamlining the molecular testing workflow, the company aims to provide high-accuracy results in decentralized settings. NucleoBio also explores applications in food safety and environmental monitoring to broaden the impact of its detection technology.